News
CNXU
10.96
+7.24%
0.74
THE AESTHETICS GIANTS JUST CONFIRMED “OZEMPIC FACE” IS REAL — AND A NEWLY PUBLIC REGENERATIVE PLAYER WANTS TO COMPETE FOR IT
Reuters · 1d ago
Conexeu Sciences opens Vancouver R&D facility at adMare M4 Innovation Centre
PUBT · 1d ago
Conexeu Sciences: Hanging On The FDA 510(k) Pathway Submission
Seeking Alpha · 3d ago
Conexeu Sciences director Ana Lucia Bastiani-Posner files initial beneficial ownership statement
PUBT · 3d ago
Conexeu Sciences director, 10% owner Lynn Sebastian Purcell reports $162,000 common share purchase
PUBT · 3d ago
Opening Day: Kardigan races higher after debut on Nasdaq
TipRanks · 4d ago
This Credo Technology Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Benzinga · 4d ago
Conexeu Sciences Price Target Announced at $20.00/Share by HC Wainwright & Co.
Dow Jones · 4d ago
Conexeu Sciences Initiated at Buy by HC Wainwright & Co.
Dow Jones · 4d ago
HC Wainwright & Co. Initiates Coverage On Conexeu Sciences with Buy Rating, Announces Price Target of $20
Benzinga · 4d ago
Weekly Report: what happened at CNXU last week (0615-0619)?
Weekly Report · 4d ago
Conexeu Sciences initiated with a Buy at H.C. Wainwright
TipRanks · 4d ago
CONEXEU SCIENCES INC. <CNXU.O>: H.C. WAINWRIGHT INITIATES COVERAGE WITH BUY RATING AND TARGET PRICE $20
Reuters · 4d ago
U.S. RESEARCH ROUNDUP-Baldwin Insurance Group, Diamondback Energy, Visteon
Reuters · 5d ago
Top Biotech Gainers: CRVO On Watch, SLP Scooped Up, LNAI Back In Compliance, NTHI Advances NEO212
NASDAQ · 06/17 03:02
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 06/16 17:06
Press Release: Fresh Off Its Nasdaq Debut, a -2-
Dow Jones · 06/16 12:15
Press Release: Fresh Off Its Nasdaq Debut, a Regenerative-Medicine Upstart Is Stacking Its Board With Big-Pharma Firepower
Dow Jones · 06/16 12:15
Conexeu net loss widens to USD 2.3 million in Q2 FY26; revenue flat with no revenue
PUBT · 06/15 20:31
Opening Day: SpaceX jumps on first day of trading, surges past $2T
TipRanks · 06/15 15:07
More
Webull provides a variety of real-time CNXU stock news. You can receive the latest news about CONEXEU SCIENCES INC through multiple platforms. This information may help you make smarter investment decisions.
About CNXU
Conexeu Sciences Inc. is an early-stage medical technology company. The Company is focused on developing regenerative biomaterials that address significant needs in wound care, dentistry, and aesthetics. The Company is focused on providing physicians with device-based solutions for healing, restoring soft tissue, and improving patient outcomes across multiple clinical settings. Its core device candidate, CXU, is a temperature-responsive ECM scaffold formulation intended to transition in-situ to a gel-like extra cellular matrix (ECM) within approximately minutes (Ten-Minute Tissue). The Company operates and manages its business in one operating segment, which is developing and commercializing novel cellular therapies for skin restoration in wound care and aesthetics.